WHAT IS CLAIMED IS:

1. Use of *N*-[4-(6-fluoro-3,4-dihydro-1*H*-isoquinolin-2-yl)-2,6-dimethylphenyl]-3,3-dimethylbutanamide in the manufacture of a medicament for treating pain in a human.

2. The use of claim 1, wherein the medicament is formulated for administration in combination with an opioid analgesic.

3. The use one of claims or claim 2, wherein the *N*-[4-(6-fluoro-3,4-dihydro-1*H*-isoquinolin-2-yl)-2,6-dimethylphenyl]-3,3-dimethylbutanamide enhances the opening of a Kv7 potassium channel in the human.

4. The use of any one of claims 1-3, wherein the pain is nociceptive pain, neuropathic pain, or a combination thereof.

5. The use of claim 4, wherein the pain is nociceptive pain.

6. The use of claim 4, wherein the pain is neuropathic pain.

7. The use of any one of claims 1-6, wherein the pain is acute pain.

8. The use of any one of claims 1-6, wherein the pain is chronic pain.

9. The use of any one of claims 1-8, wherein the pain is moderate or severe pain.

10. The use of any one of claims 1-9, wherein the pain is of tumor origin.

11. The use of any one of claims 1-10, wherein the pain is breakthrough pain

12. The use of any one of claims 1-3, wherein the pain is inflammatory pain.

13. The use of claim 12, wherein the inflammatory pain is associated with chronic inflammatory disease of the joints.

14. The use of claim 12, wherein the inflammatory pain is associated with arthritis.

15. The use of claim 12, wherein the inflammatory pain is associated with a Type I or Type II diabetes mellitus.

16. The use of claim 15, wherein the inflammatory pain is associated with diabetic complications.

17. The use of any one of claims 1-3, wherein the pain is associated with a migraine, including migraine without aura ("common migraine"), migraine with aura ("classic migraine"), migraine without headache, basilar migraine, familial hemiplegic migraine, migrainous infarction, migraine with prolonged aura, or a combination thereof.

18. The use of any one of claims 1-17, wherein *N*-[4-(6-fluoro-3,4-dihydro-1*H*-isoquinolin-2-yl)-2,6-dimethylphenyl]-3,3-dimethylbutanamide is administered at a dose of 2 to 200 mg to the human.

19. The use of any one of claims 1-17, wherein *N*-[4-(6-fluoro-3,4-dihydro-1*H*-isoquinolin-2-yl)-2,6-dimethylphenyl]-3,3-dimethylbutanamide is administered at a dose of 5-1000 mg per day to the human.

20. The use of any one of claims 1-19, wherein *N*-[4-(6-fluoro-3,4-dihydro-1*H*-isoquinolin-2-yl)-2,6-dimethylphenyl]-3,3-dimethylbutanamide is administered at a dose of 0.05-20 mg/kg to the human.

21. The use of any one of claims 1-20, wherein *N*-[4-(6-fluoro-3,4-dihydro-1*H*-isoquinolin-2-yl)-2,6-dimethylphenyl]-3,3-dimethylbutanamide is orally administered to the human.

22. The use of claim 21, wherein *N*-[4-(6-fluoro-3,4-dihydro-1*H*-isoquinolin-2-yl)-2,6-dimethylphenyl]-3,3-dimethylbutanamide is orally administered to the human from between about 30 minutes before to about 2 hours after eating a meal.

23. The use of claim 22, wherein *N*-[4-(6-fluoro-3,4-dihydro-1*H*-isoquinolin-2-yl)-2,6-dimethylphenyl]-3,3-dimethylbutanamide is orally administered to the human during a meal or within 15 minutes after eating a meal.